MET and non-small cell lung carcinoma: In a retrospective study that included eight cases of NSCLC with METex14 and four cases of NSCLC with MET amplification treated with ICI, median PFS with ICI was 4.0 months (95% CI, 2.4–NR) in patients with METex14 and 4.9 months (95% CI, 2.4–NR) in patients with MET amplification (46).